IceCure Medical initiated with a Buy at Alliance Global

Alliance Global analyst Scott Henry initiated coverage of IceCure Medical (ICCM) with a Buy rating and $1 price target IceCure is an Israel-based medical technology company developing and commercializing the ProSense Cryoablation System, a minimally-invasive treatment that uses extreme cold to freeze and accurately destroy tumors, the analyst tells investors in a research note. The firm says the company’s expansion into early-stage breast cancer could benefit from recent approvals and an improving reimbursement environment.